• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Hemispherx seeks approval for Ampligen in Latin America

Nielk

Nielk

Senior Member
Messages
6,970
http://www.cfstreatmentguide.com/1/...s-approval-for-ampligen-in-latin-america.html

PHILADELPHIA, March 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it and its partner in Latin America, GP Pharm, are planning on making applications in Chile, Peru and Uruguay for regulatory approval of Ampligen® to treat CFS.

Jorge Braver, President of GP Pharm, said, "In Latin American countries, in order to file for regulatory approval of a product, companies must first gain clearance of the trademarks in each country. We have now received notification of clearance of the trademark "Rintamod" (Ampligen® in the US) in these three countries and are now planning on making the filings for regulatory approval."

Thomas K. Equels, Executive Vice Chairman of Hemispherx, said, "This is our next step in Hemispherx's global strategy for Ampligen® following our July 18, 2012 announcement regarding a filing for regulatory approval of Ampligen® ('Rintamod') to treat CFS in Argentina."
Click to expand...
 
You must log in or register to reply here.